Scinai ImmunotherapeuticsNASDAQ: SCNI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

11 May 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$2.53 M
-94%vs. 3y high
6%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
12%vs. sector
-47%vs. 3y high
76%vs. sector

Price

regular market | Thu, 21 Nov 2024 14:30:00 GMT
$3.02+$0.09(+3.07%)

Dividend

No data over the past 3 years
$284.00 K-$2.32 M

Analysts recommendations

Institutional Ownership

SCNI Latest News

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
prnewswire.com22 November 2024 Sentiment: -

JERUSALEM , Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
prnewswire.com16 September 2024 Sentiment: POSITIVE

JERUSALEM, Israel , Sept. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
prnewswire.com21 August 2024 Sentiment: POSITIVE

JERUSALEM , Aug. 21, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has closed the previously announced Loan Restructuring Agreement (the "Restructuring Agreement") with its lender, the European Investment Bank (the "EIB").

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
prnewswire.com20 August 2024 Sentiment: POSITIVE

JERUSALEM , Aug. 20, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has entered into a $2 million Investment Commitment Agreement (the "Agreement") with RK Stone Miami LLC, an affiliate of Mr.

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
prnewswire.com13 August 2024 Sentiment: POSITIVE

JERUSALEM , Aug. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has signed a definitive Loan Restructuring Agreement (the "Restructuring Agreement") with its lender, the European Investment Bank (the "EIB").

Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
investorplace.com15 July 2024 Sentiment: POSITIVE

Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is taking off on Monday after the development stage biopharmaceutical company announced results from an early study. Scinai Immunotherapeutics revealed results from an in-vivo preclinical study of anti IL-17A/F VHH antibody fragment NanoAb.

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
prnewswire.com08 July 2024 Sentiment: POSITIVE

JERUSALEM , July 8, 2024 /PRNewswire/ --  Scinai Immunotherapeutics Ltd . (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has received an updated non-binding Letter of Intent ("LoI") from the European Investment Bank (the "EIB").

Scinai Publishes Q1 2024 Financial Results and Provides Business Update
prnewswire.com02 July 2024 Sentiment: POSITIVE

JERUSALEM , July 2, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the quarter ended March 31, 2024, and provided a business update.

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
prnewswire.com13 June 2024 Sentiment: POSITIVE

JERUSALEM , June 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has received a non-binding Letter of Intent ("LoI") from the European Investment Bank (the "EIB").

What type of business is Scinai Immunotherapeutics?

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

What sector is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics is in the Healthcare sector

What industry is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics is in the Biotechnology industry

What country is Scinai Immunotherapeutics from?

Scinai Immunotherapeutics is headquartered in Israel

When did Scinai Immunotherapeutics go public?

Scinai Immunotherapeutics initial public offering (IPO) was on 11 May 2015

What is Scinai Immunotherapeutics website?

https://www.scinai.com

Is Scinai Immunotherapeutics in the S&P 500?

No, Scinai Immunotherapeutics is not included in the S&P 500 index

Is Scinai Immunotherapeutics in the NASDAQ 100?

No, Scinai Immunotherapeutics is not included in the NASDAQ 100 index

Is Scinai Immunotherapeutics in the Dow Jones?

No, Scinai Immunotherapeutics is not included in the Dow Jones index

When was Scinai Immunotherapeutics the previous earnings report?

No data

When does Scinai Immunotherapeutics earnings report?

Next earnings report date is not announced yet